AVDL

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: JAZZ NBIX BMRN SUPN XENE AXSM VYGR PRTA KNSA NERV

| Held by: VTI IWM VXF IWO PJP SCHA VTWO FYC XPH IHE

Index	RUT	P/E	-	EPS (ttm)	-0.01	Insider Own	4.48%	Shs Outstand	97.23M	Perf Week	-0.64%
Market Cap	1.82B	Forward P/E	21.82	EPS next Y	0.86	Insider Trans	0.00%	Shs Float	93.26M	Perf Month	31.67%
Enterprise Value	1.77B	PEG	-	EPS next Q	0.16	Inst Own	85.98%	Short Float	10.70%	Perf Quarter	46.75%
Income	-0.28M	P/S	7.32	EPS this Y	154.40%	Inst Trans	3.15%	Short Ratio	4.06	Perf Half Y	99.25%
Sales	248.52M	P/B	18.52	EPS next Y	209.09%	ROA	-0.16%	Short Interest	9.98M	Perf YTD	78.02%
Book/sh	1.01	P/C	19.87	EPS next 5Y	-	ROE	-0.32%	52W High	19.06 -1.84%	Perf Year	25.91%
Cash/sh	0.94	P/FCF	49.46	EPS past 3/5Y	27.03% 10.39%	ROIC	-0.21%	52W Low	6.38 193.26%	Perf 3Y	169.99%
Dividend Est.	-	EV/EBITDA	215.31	Sales past 3/5Y	- 23.35%	Gross Margin	94.47%	Volatility	1.23% 2.88%	Perf 5Y	271.23%
Dividend TTM	-	EV/Sales	7.10	EPS Y/Y TTM	99.60%	Oper. Margin	1.82%	ATR (14)	0.42	Perf 10Y	16.72%
Dividend Ex-Date	-	Quick Ratio	2.37	Sales Y/Y TTM	79.88%	Profit Margin	-0.11%	RSI (14)	74.49	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.76	EPS Q/Q	100.73%	SMA20	7.99%	Beta	1.28	Target Price	19.89
Payout	-	Debt/Eq	0.38	Sales Q/Q	54.86%	SMA50	16.35%	Rel Volume	0.79	Prev Close	18.96
Employees	188	LT Debt/Eq	0.37	Earnings	Nov 04 AMC	SMA200	69.25%	Avg Volume	2.46M	Price	18.71
IPO	Jun 07, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	-100.00% 5.29%	Trades		Volume	1,934,887	Change	-1.32%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-23-25	Downgrade	H.C. Wainwright	Buy → Neutral	$20
Sep-03-25	Initiated	Wells Fargo	Equal Weight	$16
Jul-18-25	Resumed	H.C. Wainwright	Buy	$22
Feb-11-25	Initiated	Deutsche Bank	Buy	$12
Jun-12-24	Initiated	Rodman & Renshaw	Buy	$27
Mar-05-24	Reiterated	Oppenheimer	Outperform	$27 → $29
Mar-05-24	Reiterated	Needham	Buy	$20 → $22
Mar-05-24	Reiterated	H.C. Wainwright	Buy	$21 → $25
Feb-06-24	Initiated	UBS	Buy	$21
Nov-30-22	Upgrade	Jefferies	Hold → Buy	$6.50 → $11
Aug-10-22	Downgrade	Jefferies	Buy → Hold	$6 → $8
Jul-28-22	Resumed	Craig Hallum	Buy	$15.50 → $12
May-26-22	Downgrade	Stifel	Buy → Hold	$9 → $2
Sep-23-21	Initiated	Needham	Buy	$17
Jul-31-20	Initiated	Oppenheimer	Outperform	$19
Jul-21-20	Initiated	SVB Leerink	Outperform	$17
Jun-30-20	Initiated	H.C. Wainwright	Buy	$15
Apr-03-20	Initiated	Jefferies	Buy	$14
Mar-12-20	Initiated	Stifel	Buy	$14
Feb-26-20	Initiated	Piper Sandler	Overweight	$14

Show Previous Ratings

Nov-05-25 11:10AM	FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc (GlobeNewswire)
05:00AM	New Strong Sell Stocks for Nov. 5 (Zacks)
Nov-04-25 04:01PM	Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-25 01:45PM	Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised (Zacks)
Oct-28-25 09:42AM	Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls (The Fly)
10:27AM	Loading…
Oct-23-25 10:27AM	ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition (Zacks)
09:39AM	LendingClub upgraded, Enphase Energy downgraded: Wall Street's top analyst calls (The Fly)
05:25AM	Alkermes to acquire Avadel for $2.1bn (Pharmaceutical Technology)
Oct-22-25 04:11PM	Why Alkermes' $2.1 Billion Avadel Buyout Was 'Very Confusing' - At First (Investor's Business Daily)
07:36AM	Alkermes expands sleep portfolio with acquisition worth up to $2.1B (BioPharma Dive)
07:00AM	Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc (PR Newswire)
06:30AM	Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement (GlobeNewswire)
Oct-13-25 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-07-25 11:32AM	SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal (Zacks)
Oct-06-25 09:51AM	ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up (Zacks)
12:18PM	Loading…
Sep-26-25 12:18PM	Encompass Health Opens First Connecticut Rehab Hospital in Danbury (Zacks)
Sep-16-25 08:00AM	Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding (GlobeNewswire)
Sep-10-25 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-25 08:00AM	Avadel Pharmaceuticals to Present New Data on LUMRYZ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025 (GlobeNewswire) +5.14%
Sep-04-25 02:36PM	Avadel Pharmaceuticals (AVDL) Attracts Institutional Investment (Insider Monkey)
06:23AM	Avadel secures rights to develop valiloxybate globally (Pharmaceutical Technology)
Sep-03-25 04:30PM	Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd (GlobeNewswire)
Sep-02-25 09:40AM	Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year? (Zacks)
04:06AM	Avadel Pharmaceuticals plc (AVDL)'s LUMRYZ Sales Surge 64% in Breakout Quarter (Insider Monkey)
Aug-29-25 08:00AM	Avadel Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-28-25 12:50PM	HUM Expands Musculoskeletal Care Access With New Value-Based Tie-Ups (Zacks)
Aug-27-25 09:55AM	Does Avadel (AVDL) Have the Potential to Rally 27.95% as Wall Street Analysts Expect? (Zacks)
Aug-26-25 11:22AM	Acadia & ECU Health Expand Behavioral Care Access in North Carolina (Zacks)
Aug-25-25 02:03PM	Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock? (Zacks)
Aug-20-25 12:45PM	Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU (Zacks)
12:01PM	Loading…
Aug-18-25 12:01PM	Are Options Traders Betting on a Big Move in Avadel Pharmaceuticals Stock? (Zacks)
Aug-15-25 09:40AM	Is Armata Pharmaceuticals (ARMP) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-11-25 09:55AM	Wall Street Analysts Predict a 37.25% Upside in Avadel (AVDL): Here's What You Should Know (Zacks)
Aug-07-25 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +14.77%
07:10AM	Avadel: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance (GlobeNewswire)
Jul-31-25 08:00AM	Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7 (GlobeNewswire)
Jul-21-25 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-14-25 07:00AM	ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders (Business Wire)
Jul-10-25 11:40AM	Avadel Pharmaceuticals Receives Unanimous Appeals Court Affirmation for LUMRYZ FDA Approval (Insider Monkey)
Jun-30-25 07:00AM	Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation (GlobeNewswire)
07:00AM	ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders (Business Wire)
Jun-29-25 09:00PM	Avadel Shareholder Seeks Ousting Drugmaker's Entire Board (The Wall Street Journal)
Jun-16-25 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:55AM	Wall Street Analysts See an 81.61% Upside in Avadel (AVDL): Can the Stock Really Move This High? (Zacks)
Jun-13-25 12:20PM	Surging Earnings Estimates Signal Upside for Avadel (AVDL) Stock (Zacks)
Jun-05-25 07:30AM	Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia (GlobeNewswire)
May-30-25 12:04AM	Avadel Pharmaceuticals plc (AVDL) Showcases LUMRYZ Success with 14 Abstracts, 4 Oral Presentations at SLEEP 2025 (Insider Monkey)
May-29-25 04:05PM	Avadel Pharmaceuticals to Present New Data on LUMRYZ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025 (GlobeNewswire)
09:55AM	Wall Street Analysts Think Avadel (AVDL) Could Surge 97.68%: Read This Before Placing a Bet (Zacks)
08:00AM	Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 12:00PM	All You Need to Know About Avadel (AVDL) Rating Upgrade to Buy (Zacks)
May-13-25 04:15PM	Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer (GlobeNewswire) -5.84% -5.54%
08:00AM	Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-12-25 12:20PM	Earnings Estimates Moving Higher for Avadel (AVDL): Time to Buy? (Zacks)
09:55AM	Wall Street Analysts Believe Avadel (AVDL) Could Rally 100.21%: Here's is How to Trade (Zacks)
May-08-25 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
03:09AM	Avadel Pharmaceuticals PLC (AVDL) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-07-25 12:45PM	Avadel Pharmaceuticals plc (AVDL) Q1 2025 Earnings Call Transcript (Seeking Alpha) +9.61%
11:00AM	Appeals court reverses-in-part, vacates-in part ruling in Avadel-Jazz fight (TipRanks)
07:13AM	Avadel: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
May-06-25 12:30PM	Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction (GlobeNewswire)
Apr-30-25 08:00AM	Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7 (GlobeNewswire)
Apr-17-25 08:00AM	Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience (GlobeNewswire)
Apr-10-25 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.71%
Apr-08-25 01:30PM	Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-25 08:00AM	Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference (GlobeNewswire)
Mar-25-25 08:00AM	Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians (GlobeNewswire)
Mar-20-25 01:03PM	3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets (SeekingAlpha)
Mar-05-25 08:00AM	Avadel Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-04-25 02:02AM	Avadel Pharmaceuticals PLC (AVDL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Mar-03-25 07:28AM	Avadel: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-01-25 07:32AM	Is Avadel Pharmaceuticals plc (AVDL) the Best Small Cap Pharma Stocks to Buy Now? (Insider Monkey)
Feb-28-25 07:10AM	Avadel Pharmaceuticals PLC (AVDL) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-24-25 04:05PM	Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3 (GlobeNewswire)
08:00AM	Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales (GlobeNewswire)
Feb-20-25 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-10-25 09:00AM	ASL Strategic Value Fund Letter to Avadel Pharmaceuticals (AVDL: NASDAQ) Board of Directors (Business Wire) +12.08%
Jan-22-25 08:00AM	Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement (GlobeNewswire)
Jan-09-25 02:01AM	Avadel Pharmaceuticals PLC (AVDL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Jan-08-25 04:15PM	Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch (GlobeNewswire) -26.10%
Jan-07-25 07:03AM	Avadel Pharmaceuticals PLC (AVDL) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Jan-06-25 04:05PM	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-03-25 08:00AM	Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8 (GlobeNewswire)
Dec-11-24 08:00AM	Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy (GlobeNewswire)
Nov-13-24 08:00AM	Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -8.59%
02:09AM	Avadel Pharmaceuticals PLC (AVDL) Q3 2024 Earnings Call Highlights: Strong Patient Growth and ... (GuruFocus.com)
Nov-12-24 07:21AM	Avadel: Q3 Earnings Snapshot (Associated Press Finance) -19.33%
07:00AM	Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-11-24 07:10AM	Avadel Pharmaceuticals PLC (AVDL) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 08:00AM	Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12 (GlobeNewswire)
Nov-01-24 11:41AM	US court upholds Avadels narcolepsy drug approval amid exclusivity battle (Pharmaceutical Technology)
Oct-31-24 07:00AM	Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation (GlobeNewswire) +19.83%
Oct-24-24 08:00AM	Avadel Pharmaceuticals and nference Announce Publication of Real-World Data in Sleep Advances (GlobeNewswire)
Oct-18-24 04:34PM	Avadel wins FDA approval for narcolepsy drug Lumryz in children (Pharmaceutical Technology)
Oct-17-24 09:41AM	Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy (GlobeNewswire) +5.14%
Oct-09-24 05:36PM	Avadel Pharmaceuticals PLC (AVDL) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Sep-25-24 08:00AM	Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting Agent (GlobeNewswire)

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Palczuk Linda	Director	Jan 21 '25	Buy	7.93	5,000	39,640	67,900	Jan 22 04:13 PM
Thornton Peter J.	Director	Jan 13 '25	Buy	8.04	10,000	80,450	104,055	Jan 14 04:24 PM
Ende Eric J	Director	Jan 13 '25	Buy	7.84	30,000	235,218	208,900	Jan 14 04:22 PM
MCHUGH THOMAS S	Chief Financial Officer	Dec 13 '24	Buy	10.44	2,300	24,019	87,800	Dec 16 07:00 AM
MCHUGH THOMAS S	Chief Financial Officer	Dec 11 '24	Buy	10.49	5,000	52,432	85,500	Dec 12 07:00 AM
Divis Gregory J	Chief Executive Officer	Dec 06 '24	Buy	9.98	9,598	95,759	9,598	Dec 10 06:14 PM
Divis Gregory J	Chief Executive Officer	Dec 09 '24	Buy	9.82	402	3,948	10,000	Dec 10 06:14 PM
Glass Geoffrey Michael	Director	Dec 10 '24	Buy	9.84	20,279	199,641	75,904	Dec 10 06:13 PM
Palczuk Linda	Director	Dec 06 '24	Buy	10.19	3,000	30,568	66,400	Dec 10 07:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Avadel Pharmaceuticals plc

Upgrade your FINVIZ experience